CY1119114T1 - ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[2,3-b] ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ CB2 - Google Patents

ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[2,3-b] ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ CB2

Info

Publication number
CY1119114T1
CY1119114T1 CY20171100785T CY171100785T CY1119114T1 CY 1119114 T1 CY1119114 T1 CY 1119114T1 CY 20171100785 T CY20171100785 T CY 20171100785T CY 171100785 T CY171100785 T CY 171100785T CY 1119114 T1 CY1119114 T1 CY 1119114T1
Authority
CY
Cyprus
Prior art keywords
pyrolol
agons
receptor
pyrimidine derivatives
pyrimidine
Prior art date
Application number
CY20171100785T
Other languages
English (en)
Inventor
Uwe Grether
Atsushi Kimbara
Matthias Nettekoven
Stephan Roever
Mark Rogers-Evans
Tanja Schulz-Gasch
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of CY1119114T1 publication Critical patent/CY1119114T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η εφεύρεση σχετίζεται με μιά ένωση τύπου (I) όπου Α και R1 έως R3 ορίζονται όπως στην περιγραφή και στις αξιώσεις. Η ένωση τύπου (I) μπορεί να χρησιμοποιηθεί ως φάρμακο.
CY20171100785T 2013-05-02 2017-07-24 ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[2,3-b] ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ CB2 CY1119114T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13166296 2013-05-02
PCT/EP2014/058648 WO2014177527A1 (en) 2013-05-02 2014-04-29 Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists
EP14720136.2A EP2991988B1 (en) 2013-05-02 2014-04-29 Pyrrolo[2,3-d]pyrimidine derivatives as cb2 receptor agonists

Publications (1)

Publication Number Publication Date
CY1119114T1 true CY1119114T1 (el) 2018-02-14

Family

ID=48190401

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100785T CY1119114T1 (el) 2013-05-02 2017-07-24 ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[2,3-b] ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ CB2

Country Status (35)

Country Link
US (1) US9580435B2 (el)
EP (1) EP2991988B1 (el)
JP (1) JP6454689B2 (el)
KR (1) KR20160002857A (el)
CN (1) CN105164133B (el)
AR (1) AR096153A1 (el)
AU (1) AU2014261546B2 (el)
BR (1) BR112015027394A8 (el)
CA (1) CA2907691A1 (el)
CL (1) CL2015003196A1 (el)
CR (1) CR20150555A (el)
CY (1) CY1119114T1 (el)
DK (1) DK2991988T3 (el)
EA (1) EA028123B1 (el)
ES (1) ES2635632T3 (el)
HK (1) HK1213559A1 (el)
HR (1) HRP20171099T1 (el)
HU (1) HUE035333T2 (el)
IL (1) IL242162B (el)
LT (1) LT2991988T (el)
MA (1) MA38555B1 (el)
MX (1) MX2015014081A (el)
MY (1) MY182237A (el)
NZ (1) NZ712030A (el)
PE (1) PE20160039A1 (el)
PH (1) PH12015502409B1 (el)
PL (1) PL2991988T3 (el)
PT (1) PT2991988T (el)
RS (1) RS56313B1 (el)
SG (1) SG11201509029PA (el)
SI (1) SI2991988T1 (el)
TW (1) TWI680129B (el)
UA (1) UA116801C2 (el)
WO (1) WO2014177527A1 (el)
ZA (1) ZA201507008B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE041760T2 (hu) 2013-09-06 2019-05-28 Hoffmann La Roche Triazolo[4,5-d]pirimidin-származékok mint CBb2-receptor antagonisták
BR112017009629A2 (pt) * 2014-11-07 2017-12-19 Hoffmann La Roche triazolo [4,5-d] pirimidinas como agonistas do receptor canabinoide 2
EP3475280B1 (en) 2016-06-23 2020-04-08 H. Hoffnabb-La Roche Ag Novel [1,2,3]triazolo[4,5-d]pyrimidine derivatives
EP3475283B1 (en) 2016-06-23 2021-08-11 F. Hoffmann-La Roche AG Novel[1,2,3]triazolo[4,5-d]pyrimidine derivatives
CR20180615A (es) 2016-06-23 2019-03-05 Hoffmann La Roche Nuevos derivados de [1,2,3]triazol[4,5-d]pirimidina
CN109311886B (zh) 2016-06-23 2021-11-09 豪夫迈·罗氏有限公司 [1,2,3]三唑并[4,5-d]嘧啶衍生物
AU2021341508A1 (en) 2020-09-10 2023-05-25 Precirix N.V. Antibody fragment against fap
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001234958A1 (en) 2000-02-11 2001-08-20 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
DE10219435A1 (de) 2002-05-02 2003-11-13 Bayer Cropscience Ag Substituierte Pyrazolo-pyrimidin-4-one
AR042667A1 (es) * 2002-12-26 2005-06-29 Taisho Pharmaceutical Co Ltd Derivados de pirrolopirimidina y pirrolopiridina sustituidos con un grupo amino ciclico
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
PT1999132E (pt) * 2006-03-30 2012-10-02 Irm Llc Azolopirimidinas como inibidores de atividade do recetor canabinóide 1
ES2395583T3 (es) * 2007-05-10 2013-02-13 Ge Healthcare Limited IMIDAZOL (1,2-A)PIRIDINAS y compuestos relacionados con actividad frente a los receptores cannabinoides CB2
WO2009032754A2 (en) * 2007-08-31 2009-03-12 Kalypsys, Inc. Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease
US20100227845A1 (en) 2007-10-18 2010-09-09 Zhicai Wu Substituted 1,2,4-oxadiazoles and analogs thereof as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
UA104010C2 (en) * 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
WO2010118367A2 (en) 2009-04-10 2010-10-14 Progenics Pharmaceuticals, Inc. Antiviral pyrimidines
EA201290147A1 (ru) * 2009-10-15 2012-11-30 Пфайзер Инк. Пирроло[2,3-d]пиримидиновые соединения
US9321727B2 (en) 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
UA111640C2 (uk) 2011-11-08 2016-05-25 Ф. Хоффманн-Ля Рош Аг ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
EP2870139B1 (en) 2012-07-04 2016-06-15 F.Hoffmann-La Roche Ag Novel adamantyl derivatives as cannabinoid receptor 2 agonists
PE20151089A1 (es) 2012-12-07 2015-08-06 Hoffmann La Roche Piridin-2-amidas utiles como agonistas de cb2
MX2015007156A (es) 2012-12-07 2015-10-14 Hoffmann La Roche Piridina-2-amidas utiles como agonistas receptores de canabinoides 2 (cb2).
IN2015DN03145A (el) 2012-12-07 2015-10-02 Hoffmann La Roche
MX2015007155A (es) 2012-12-07 2015-10-14 Hoffmann La Roche Nuevos derivados de piridina.
PL2964646T3 (pl) 2013-03-07 2017-09-29 F.Hoffmann-La Roche Ag Nowe pochodne pirazolu
ES2680935T3 (es) 2013-05-02 2018-09-11 F. Hoffmann-La Roche Ag Derivados de purina como agonistas del receptor CB2

Also Published As

Publication number Publication date
US20160046637A1 (en) 2016-02-18
ES2635632T3 (es) 2017-10-04
TW201522343A (zh) 2015-06-16
AU2014261546B2 (en) 2018-01-18
CR20150555A (es) 2015-11-20
RS56313B1 (sr) 2017-12-29
MA38555B1 (fr) 2018-04-30
EA028123B1 (ru) 2017-10-31
TWI680129B (zh) 2019-12-21
NZ712030A (en) 2021-03-26
LT2991988T (lt) 2017-08-10
EA201591939A1 (ru) 2016-03-31
PE20160039A1 (es) 2016-01-28
AR096153A1 (es) 2015-12-09
CN105164133B (zh) 2018-02-13
HRP20171099T1 (hr) 2017-10-06
BR112015027394A8 (pt) 2018-01-30
HUE035333T2 (en) 2018-05-02
CN105164133A (zh) 2015-12-16
PH12015502409A1 (en) 2016-02-22
PL2991988T3 (pl) 2017-10-31
HK1213559A1 (zh) 2016-07-08
CL2015003196A1 (es) 2016-06-03
SG11201509029PA (en) 2015-12-30
JP6454689B2 (ja) 2019-01-16
SI2991988T1 (sl) 2017-09-29
WO2014177527A1 (en) 2014-11-06
EP2991988A1 (en) 2016-03-09
MA38555A1 (fr) 2017-09-29
ZA201507008B (en) 2017-08-30
MX2015014081A (es) 2015-12-11
JP2016517874A (ja) 2016-06-20
US9580435B2 (en) 2017-02-28
PT2991988T (pt) 2017-07-25
DK2991988T3 (en) 2017-08-21
KR20160002857A (ko) 2016-01-08
EP2991988B1 (en) 2017-05-31
MY182237A (en) 2021-01-18
AU2014261546A1 (en) 2015-09-24
UA116801C2 (uk) 2018-05-10
CA2907691A1 (en) 2014-11-06
IL242162B (en) 2019-06-30
BR112015027394A2 (pt) 2017-07-25
PH12015502409B1 (en) 2016-02-22

Similar Documents

Publication Publication Date Title
CY1119114T1 (el) ΠΑΡΑΓΩΓΑ ΠΥΡΡΟΛΟ[2,3-b] ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ CB2
CY1117147T1 (el) Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2
CY1117878T1 (el) Πυριδινo-2-αμιδια χρησιμα ως αγωνιστες του cb2
CY1118950T1 (el) Νεα παραγωγα πυραζολιου
CR20150470A (es) Derivados de triazolona de piridinilo y piridinilo fusionado
TR201911140T4 (tr) Btk inhibitörleri olarak heteroaril bileşikleri ve bunların kullanımları.
CY1115945T1 (el) Παραγωγα πυραζολοκινολινονης, η παρασκευη τους και η θεραπευτικη τους χρηση
CY1116984T1 (el) ΠΑΡΑΓΩΓΑ [1,2,3]ΤΡΙΑΖΟΛΟ[4,5-d]ΠΥΡΙΜΙΔΙΝΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΥΠΟΔΟΧΕΑ ΚΑΝΝΑΒΙΝΟΕΙΔΩΝ 2
CR20150250A (es) Nuevos derivados de piridina
UY34602A (es) ?Derivados de bencimidazolil- e imidazopiridinil-metilamina?
UA110880C2 (uk) Заміщені амідином бета-лактами, їх одержання та застосування як антибактеріальних засобів
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
TR201900662T4 (tr) Cb2 reseptör antagonistleri olarak triazolo[4,5-d]pirimidin türevleri.
MX2015003538A (es) Derivados de 3-fenilisoxazolina con accion herbicida.
CY1119619T1 (el) Παραγωγα πυριδιν-4-υλιου
PH12015502471A1 (en) Purine derivatives as cb2 receptor agonists
CR20150440A (es) Nuevos derivados de piridina
CR20160083A (es) Compuestos con actividad pesticida
DOP2016000021A (es) Imidazotiazol sulfonamidas como nematicidas
ECSP15050110A (es) Derivados de triazina
MX2015016766A (es) Nuevos derivados de tetrazolona.
MX2016006807A (es) Derivados de imidazol.
UA89428U (en) 2-(14,15-dioxa-7-azadispirro[5,1,5,2]pentadec -7-yl)ethanol